Development of fluorine-18-labeled 5-HT1A antagonists

被引:101
作者
Lang, LX
Jagoda, E
Schmall, B
Vuong, BK
Adams, HR
Nelson, DL
Carson, RE
Eckelman, WC
机构
[1] NIH, Ctr Clin, Positron Emiss Tomog Dept, Bethesda, MD 20892 USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
D O I
10.1021/jm980456f
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We have synthesized five fluorinated derivatives of WAY 100635, N-{2-[4-(2-methoxyphenyl)piperazino]ethyl)-N-(2-pyridyl)cyclohexanecarboxamide (4a), using various acids in place of the cyclohexanecarboxylic acid (CHCA, 2a) in the reaction scheme. The five acids are 4-fluorobenzoic acid (FB, 2b), 4-fluoro-3-methylbenzoic acid (MeFB, 2c), trans-4-fluorocyclohexanecarboxylic acid (FC, 2d), 4-(fluoromethyl)benzoic acid (FMeB, 2e), and 3-nitro-4-(fluoromethyl)benzoic acid (NFMeB, 2f) (see Scheme 1). These compounds were radiolabeled with fluorine-18, and their biological properties were evaluated in rats and compared with those of [C-11]carbonyl WAY 100635 ([carbonyl-C-11]4a), [Carbonyl-C-11]4a cleared the brain with a biological half-life averaging 41 min. The metabolite-corrected blood radioactivity had a half-life of 29 min. [F-18]FCWAY ([F-18]4d) gave half-lives and intercepts comparable to [carbonyl-C-11]4a in the brain, but the blood clearance was faster. [F-18]FBWAY ([F-18]4b) showed an early rapid net efflux from the whole brain, clearing with a biological half-life of 35 min. The metabolite-corrected blood half-life was 41 min. The comparable whole brain and blood half-lives for Me[F-18]FBWAY ([F-18]4c) were 16 and 18 min, respectively. For each compound, the corresponding carboxylic acid was identified as a major metabolite in blood. Fluoride was also found after injection of [F-18]4d. However, for all compounds there was a good correlation (R > 0.97) between the differential uptake ratio (DUR, (%ID/g) x body weight (g)/100) in individual rat brain regions at 30 min after injection and the concentration of receptors as determined by in vitro quantitative autoradiography in rat. Specific binding ratios [region of interest (ROI)/ cerebellum-1] in control studies for cortex (Ctx) and hippocampus (H) were higher for [carbonyl-C-11]4a and [F-18]4d compared to [F-18]4b and [F-18]4c. [F-18]4d has similar pharmacokinetic properties and comparable specific binding ratios to [carbonyl-11C]4a. Fifty nanomoles of 4a blocked only 30% of the specific binding of [F-18]4d, while complete blockade was obtained from co-injection of 200 nmol of 4a (H/Cb-1 from 17.2 to 0.6). [F-18]4b and [F-18]4c showed lower specific binding ratios than [carbonyl-C-11]4a and [F-18]4d. [F-18]4c was superior to [F-18]4b since its specific binding was more readily blocked by 4a. These studies suggest that [F-18]4c should be a useful compound to assess dynamic changes in serotonin levels while [F-18]4d, with its high contrast and F-18 label, should provide better statistics and quantification for static measurement of 5-HT1A receptor distribution.
引用
收藏
页码:1576 / 1586
页数:11
相关论文
共 31 条
[11]   EVALUATION OF [O-METHYL-H-3]WAY-100635 AS AN IN-VIVO RADIOLIGAND FOR 5-HT1A RECEPTORS IN RAT-BRAIN [J].
HUME, SP ;
ASHWORTH, S ;
OPACKAJUFFRY, J ;
AHIER, RG ;
LAMMERTSMA, AA ;
PIKE, VW ;
CLIFFE, IA ;
FLETCHER, A ;
WHITE, AC .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 271 (2-3) :515-523
[12]   QUANTITATIVE AUTORADIOGRAPHIC CHARACTERIZATION OF THE BINDING OF [H-3] WAY-100635, A SELECTIVE 5-HT1A RECEPTOR ANTAGONIST [J].
KHAWAJA, X .
BRAIN RESEARCH, 1995, 673 (02) :217-225
[13]  
KHAWAJA X, 1995, J NEUROCHEM, V64, P2716
[14]  
Kilbourn M. R., 1990, Fluorine-18 Labelingof Radiopharmaceuticals
[15]   IN-VIVO BINDING OF [123I]4-(2'-METHOXYPHENYL)-1-[2'-(N-2''-PYRIDINYL)-P-IODOBENZAMIDO-]ETHYL-PIPERAZINE, P-MPPI, TO 5-HT1A RECEPTORS IN RAT-BRAIN [J].
KUNG, MP ;
ZHUANG, ZP ;
FREDERICK, D ;
KUNG, HF .
SYNAPSE, 1994, 18 (04) :359-366
[16]   ONE-STEP SYNTHESIS OF F-18 LABELED [F-18] N-SUCCINIMIDYL 4-(FLUOROMETHYL)BENZOATE FOR PROTEIN LABELING [J].
LANG, LX ;
ECKELMAN, WC .
APPLIED RADIATION AND ISOTOPES, 1994, 45 (12) :1155-1163
[17]   SELECTIVE IN-VIVO LABELING OF BRAIN 5-HT1A-RECEPTORS BY [H-3] WAY-100635 IN THE MOUSE [J].
LAPORTE, AM ;
LIMA, L ;
GOZLAN, H ;
HAMON, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 271 (2-3) :505-514
[18]  
MATHIS CA, 1994, LIFE SCI, V55, P403
[19]  
NewmanTancredi A, 1997, J PHARMACOL EXP THER, V282, P181
[20]   Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-C-11]WAY-100635, in monkey and human plasma by HPLC: Comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET [J].
Osman, S ;
Lundkvist, C ;
Pike, VW ;
Halldin, C ;
McCarron, JA ;
Swahn, CG ;
Ginovart, N ;
Luthra, SK ;
Bench, CJ ;
Grasby, PM ;
Wikstrom, H ;
Barf, T ;
Cliffe, IA ;
Fletcher, A ;
Farde, L .
NUCLEAR MEDICINE AND BIOLOGY, 1996, 23 (05) :627-634